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responsibility of XAbstract Method validation presents a detailed investigation of analytical method and provision
of the evidence that the method, when correctly applied, produces results that ﬁt to the purpose. In
order to achieve the method validation scope efﬁciently, experimental design presents a very useful
tool. The greatest beneﬁts of such approach could be seen in robustness testing through the
provision of very useful data about the control of the chromatograp6hic system during the routine
application. In this paper, robustness testing of the LC method proposed for the determination of
raloxifene hydrochloride and its four impurities was done employing Plackett–Burman design.
Applying this design, the effect of ﬁve real factors (acetonitrile content, sodium dodecyl sulfate
content, column temperature, pH of the mobile phase and ﬂow rate) on the corresponding
resolution factors was investigated through twelve experiments. Furthermore, the insigniﬁcance
intervals for signiﬁcant factors were calculated and the parameters for system suitability tests were
deﬁned. Eventually, the other validation parameters were tested and the effectiveness of the
proposed analytical method with a high degree of accuracy was conﬁrmed.
& 2012 Xi’an Jiaotong University. Production and hosting by Elsevier B.V. All rights reserved.ersity. Production and hosting by E
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i’an Jiaotong University.1. Introduction
Method validation can be deﬁned as the process of establish-
ing the performance characteristics and limitations of a
method, as well as the process of identifying the inﬂuences
that may change these characteristics and to which extent [1].
In general, validation should check that the method performs
adequately for the intended purpose through the whole
range of analyte concentrations to which it is applied.
In modern pharmaceutical analysis it is recommendable tolsevier B.V. All rights reserved.
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experimental design, especially in the area of chromatographic
analysis. There are many review papers dealing with the des-
cription of experimental design usage in chromatography and
one of the latest is brieﬂy discussing all kinds of designs [2].
In general, method development and validation supported
by experimental design have many advantages over tradi-
tional approach one-factor-at-the-time. The main reason is the
extraction of many useful data and drawing plenty important
conclusions from relatively small number of well planned
experiments. The signiﬁcance of experimental design applica-
tion could be seen in robustness testing which presents an
integral part of method validation. Some recommendations
and examples of robustness testing are given in the literature
[3–6].
In this paper, presented approach is applied in robustness
testing of reverse phase high performance liquid chromato-
graphic (RP-HPLC) method for the analysis of raloxifene
hydrochloride and its four impurities. Raloxifene hydrochloride
is chemically [6-hydroxy-2-(4-hydroxyphenil)benzo[b]thien-3-yl]-
[4[2-(1-piperidinyl) etoxy]phenyl]methanone hydrochloride and
its four structurally related impurities are 2-(4-hydroxyphenyl)-1-
benzotiophene-6-ol (impurity 1), piperidyl ethoxy benzoic acid
(impurity 2), dimesyl benzotiophene (impurity 3) and raloxifene
mesylate (impurity 4). Their structures are presented in the
Fig. 1.
Literature survey showed many papers dealing with iso-
cratic or gradient HPLC analysis of raloxifene in pharmaceu-
ticals [7–14]. Recently, the analysis of raloxifene employing
ultra-performance liquid chromatography (UPLC) with iso-
cratic elution was published [15]. On the other hand, there is
very limited number of papers where impurities of raloxifene
are investigated. In one of the papers, only the presence of
N-oxide was investigated [16]. Furthermore, in the paper by
Chandorkar et al. only one impurity was tracked [17]. Finally,
for the ﬁrst time, raloxifene became ofﬁcial in Ph. Eur. 7 [18]
where the method for the LC analysis of the related impurities
is proposed. For the determination of impurity A and other
unspeciﬁed impurities a gradient elution mode method was
proposed to be conducted on the base-deactivated octylsilyl
silica gel column with a mobile phase containing acetonitrile
and potassium dihydrogen phosphate solution which pH was
adjusted to 3.0 with phosphoric acid. At this point it is very
important to note that the impurities analyzed in our paper
are structurally different from those given in Ph. Eur. 7.
The only paper dealing with the chromatographic analysis of
those impurities is our previous publication mainly focused on
the evaluation of the new chromatographic function (NCRF)Fig. 1 Chemical structures of raloxifen[19]. Eventually, the papers dealing with the analysis of
raloxifene in biological samples could also be found in
literature [20–23].
Finally, the aim of this paper was to present the improve-
ment in method evaluation. Firstly, the development of back
up method for the leading method was presented. Secondly,
this method was thoroughly tested, especially its robustness,
by the application of experimental design. The proposed
method is intended for the determination of raloxifene hydro-
chloride and its listed impurities, so the validation studies are
conducted to provide a realistic survey of the effects that
might inﬂuence the method during its normal use.2. Experimental
2.1. Chemicals
All used reagents were of the analytical grade. The mobile
phase and the solvents were prepared using acetonitrile (Lab
Scan, Ireland), ortho-phosphoric acid (Carlo Erba, Italy),
sodium dodecyl sulfate – SDS (Sigma-Aldrich Chemie,
GmbH, Germany) and HPLC grade water.2.2. Chromatographic conditions
The experiments were performed on the chromatographic
system Finnigan Surveyor Thermo Scientiﬁc which consisted
of an HPLC pump, an autosampler plus and a UV/vis plus
detector. ChromQuest was used for data collection. The
analytical columns used in this study were XBridge
C18(3 mm 100 mm, 3.5 mm particle size) and SunFire C18
(3 mm 100 mm, 3.5 mm particle size). The mobile phase
composition was acetonitrile:water phase, where the water
phase consisted of SDS, while pH of the water phase was
adjusted with ortho-phosphoric acid. The other chromato-
graphic conditions were ﬂow rate 1 mL/min, column tempera-
ture 35 1C and UV detection at 254 nm.
Mixture of acetonitrile:water phase in the ratio 44:56 (v/v)
was used as solvent. Water phase was 6 mM SDS in water
with pH adjusted to 4.5 with ortho-phosphoric acid.2.3. Standard solutions
Stock solutions of raloxifene hydrochloride and the impurities
were prepared by dissolving them in the solvent to obtain thee hydrochloride and its impurities.
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0.5 mg/mL for all impurities. The prepared stock solutions
were stored at 4 1C.
2.4. Experimental data set for robustness testing
Twelve experiments deﬁned by Plackett–Burman experimental
plan were performed by varying the ﬁve real factors and six
dummy factors around the nominal level. The included real
factors and its intervals were acetonitrile content in the mobile
phase (from 43% to 45%), sodium dodecyl sulfate content in
water phase (from 5.5 mM to 6.5 mM), column temperature
(from 40 1C to 50 1C), pH of the mobile phase (from 4.3 to
4.7) and ﬂow rate (from 0.9 mL/min to 1.1 mL/min). Values
given in the brackets present their low (1) and high (þ1)
levels.
2.5. Solutions for validation
2.5.1. Solutions for linearity estimation
To evaluate the linearity of the developed method, seven
solutions of raloxifene hydrochloride in the concentration
range from 10 mg/mL to 120 mg/mL and seven solutions of
impurities (Imp. 1–Imp. 4) in the concentration range from
0.05 mg/mL to 0.6 mg/mL were in the solvent using the
appropriate standard solutions.
2.5.2. Solutions for accuracy estimation
The accuracy of the method was proved by preparing three
series of solutions containing appropriate placebo (contains all
substances from tablets except active substance and impuri-
ties), raloxifene hydrochloride, and impurities 1–4 in the
solvent. These mixtures were prepared in three levels: (a) low
level 80%: containing 80 mg/mL of raloxifene hydrochloride
and 0.4 mg/mL of the impurities; (b) medium level 100%:
containing 100 mg/mL of raloxifene hydrochloride and 0.5 mg/
mL of the impurities and (c) high level 120%: containing
120 mg/mL of raloxifene hydrochloride and 0.6 mg/mL of the
impurities.
2.5.3. Solutions for precision estimation
To prove the precision of the method, six identical solutions
of powdered tablets in the water phase containing 100 mg/mL
of raloxifene hydrochloride were prepared. The appropriate
volume of impurities stock solutions were added to all solu-
tions in order to obtain the ﬁnal concentration of 0.5 mg/mL.
2.5.4. Sample solutions
Pulverized tablet mass containing 25 mg of raloxifene hydro-
chloride was extracted with the solvent in 25 mL volumetric
ﬂask placed in ultrasonic bath for 15 min. After ﬁlling the ﬂask
to the mark, the solution was ﬁltered. This stock solution was
used to prepare six solutions containing 100 mg/mL of ralox-
ifene hydrochloride.3. Results and discussion
When HPLC method is used for the simultaneous analysis of
active substance and its impurities many different aims have to
be achieved. One of the most important aims is reaching anunambiguous separation among analyzed substances that are
usually structurally very similar. The second one is the
acquirement of their precise and accurate quantiﬁcation. For
the most efﬁcient meeting of the deﬁned aims careful pre-
liminary study should be conducted. As it could be seen from
Introduction part, there are no papers dealing with the
simultaneous determination of raloxifene hydrochloride and
its listed impurities. In our previous paper [19], this mixture
was used for the deﬁnition and evaluation of new chromato-
graphic function. During this study, XBridge C18 (3 mm 100
mm, 3.5 mm particle size column) was used and under the
chromatographic conditions stated in that publication appro-
priate separation was achieved. However, new trends in
pharmaceutical analysis suggest setting of a back-up method.
The experiments were conducted on SunFire C18 (3 mm
100 mm, 3.5 mm particle size column) and the acceptable
separation was obtained. Basically, for the separation, on
both columns, the mobile phases with acetonitrile or methanol
were tested and the changes in organic modiﬁer content were
followed by the changes of water phase content. As a water
phase, various buffer systems as well as ion pairing reagents
were investigated. pH value of the water phase was tested in
the range from 2.5 to 5.0. From a certain number of
experiments some conclusions were extracted: (a) on both
columns the optimal chromatographic separation could be
attained; (b) acetonitrile was a better choice as the organic
solvent as it affected positively on the peak symmetry,
shortened the run time, etc.; and (c) ion pairing reagent is
desirable in water phase as it enabled the adequate separation
of raloxifene hydrochloride and the analyzed impurities.
Finally, as the most suitable, the following chromatographic
conditions were chosen:
SunFire C18 (3 mm 100 mm, 3.5 mm particle size),
acetonitrile–water phase (6 mM SDS, pH 4.5 adjusted with
ortho-phosphoric acid) 44:56 (v/v), ﬂow rate of 1 mL/min,
temperature of 45 1C, and detection wavelength of 254 nm.
XBridge C18 (3 mm 100 mm, 3.5 mm particle size),
acetonitrile–water phase (4 mM SDS, pH 2.5 adjusted with
ortho-phosphoric acid) 47:53 (v/v), ﬂow rate of 1 mL/min,
temperature of 35 1C, and detection wavelength of 254 nm.
Amongst these two optimal methods the ﬁrst one was
chosen for the further testing and the second one was
denoted as a back-up method. This means, if further tests
would show that the selected method would not pass the
requirements, then all tests should be conducted with the
back-up method.
In the next step, the method’s robustness evaluation was
done using Plackett–Burman design. Theory of Plackett–
Burman design is given by Vander Heyden et al. [4] and we
have already used this design for robustness testing in the
method validation [5,24]. So, in this paper only data important
for the analyzed case are given. According to the observations
during the preliminary study, the previous experience and the
knowledge in robustness testing of LC methods, acetonitrile
content, sodium dodecyl sulfate content, column temperature,
pH of the mobile phase and ﬂow rate were selected as
investigated factors. The Plackett–Burman design was com-
pleted by the addition of six dummy factors. Dummy variables
are imaginary factors whose changes do not affect the system.
They are added in order to provide statistical evaluation of
the results and their changes from 1 to þ1 level do not have
physical meaning. As outputs, resolution factors between
B. Jancˇic´ Stojanovic´ et al.48adjacent peaks were followed. Plan of experiments deﬁned by
Plackett–Burman design and the obtained results for resolu-
tion factors are given in Table 1. Factors effects and results for
Ecritical and ME (margin of error) are calculated and presented
in Table 2.
Statistical evaluation followed the graphical presentation
using a half normal probability plot (Fig. 2A) and Pareto
chart (Fig. 2B).
Namely, when creating the half-normal plots, the n effects
are ranked in a sequence according to the increasing absolute
size of the effect. Unimportant factors are those that have
near-zero effects and important factors are those with effects
considerably removed from zero. Thus, unimportant effects
that tend to have a normal distribution centered near zero
are normally distributed around the straight line, while the
signiﬁcant effects deviate from it. Despite the strong recom-
mendation for using half-normal plots in selecting statis-
tically signiﬁcant effects, Pareto chart can sometimes be very
effective [4]. In this case, results for Pareto charts were
evaluated on the basis of t limits. All the results related to
factor’s inﬂuence are summarized in Table 3.Table 1 Plan of Plackett–Burman design and experimentally ob
Run A d1 C d2 E d3 G d4
1 þ1 þ1 1 þ1 þ1 þ1 1 1
2 1 þ1 þ1 1 þ1 þ1 þ1 1
3 þ1 1 þ1 þ1 1 þ1 þ1 þ1
4 1 þ1 1 þ1 þ1 1 þ1 þ1
5 1 1 þ1 1 þ1 þ1 1 þ1
6 1 1 1 þ1 1 þ1 þ1 1
7 þ1 1 1 1 þ1 1 þ1 þ1
8 þ1 þ1 1 1 1 þ1 1 þ1
9 þ1 þ1 þ1 1 1 1 þ1 1
10 1 þ1 þ1 þ1 1 1 1 þ1
11 þ1 1 þ1 þ1 þ1 1 1 1
12 1 1 1 1 1 1 1 1
A, acetonitrile content (%); d1, dummy 1; C, sodium dodecyl sulfat
temperature (1C); d3, dummy 3; G, pH of the mobile phase; d4, dummy
and Rs4, resolutions between adjacent peaks.
Table 2 Factors effects and results for Ecritical and ME.
Factors R1
ACN (%) 0.007
Dummy 1 0.37
SDS (mM) 0.89
Dummy 2 0.22
Temperature (1C) 0.38
Dummy 3 0.46
pH of the mobile phase 1.29
Dummy 4 0.41
Dummy 5 0.27
Flow rate (mL/min) 0.03
Dummy 6 0.15
Ecritical (a¼0.05) 0.6446
ME (0.975; m) 1.1986
ME, margin of error.It is obvious that different approaches designated quite
different factors as important. Therefore, the recommendation
is to do two or more tests (statistical and graphical) and
compare the obtained results. In this paper, we applied four
methods and the results matched for several factors but the
rest of the factors, especially the less important ones appeared
as signiﬁcant only in some tests. For the calculation of non-
signiﬁcant interval for signiﬁcant variables, results from both
statistical tests were included. For the deﬁnition of this region
equation proposed in Ref. [4] was applied
Xð0Þ
9Xð1ÞX 1ð Þ9Ecritical
29EX 9
; Xð0Þ þ
9Xð1ÞX 1ð Þ9Ecritical
29EX9
" #
ð1Þ
where X(0), X(1) and X(1) are the real values of factor X at the
levels (0), (1) and (1), respectively. Results for non-signiﬁcant
intervals of the signiﬁcant factors are given in Table 4.
Next step in the method evaluation is a development of
the control strategy which usually means a deﬁnition of the
requirements for the system suitability tests (SST) which
would be carried out each time when the method is used.tained results.
d5 K d6 Rs1 Rs2 Rs3 Rs4
1 þ1 1 2.16 7.05 3.17 13.08
1 1 þ1 2.52 10.21 0 15.42
1 1 1 2.25 9.22 2.69 11.43
þ1 1 1 4.07 8.74 0 16.80
þ1 þ1 1 0.83 10.93 0 18.92
þ1 þ1 þ1 2.58 10.96 0 13.04
1 þ1 þ1 3.89 7.06 2.95 13.03
þ1 1 þ1 1.88 8.63 3.59 11.97
þ1 þ1 1 2.15 9.13 2.62 13.34
1 þ1 þ1 1.91 11.59 0 17.49
þ1 1 þ1 1.28 7.99 2.35 11.18
1 1 1 1.67 11.09 2.53 16.36
e (SDS) content in water phase (mM); d2, dummy 2; E, column
4; d5, dummy 5; K, ﬂow rate (mL/min); d6, dummy 6; Rs1, Rs2, Rs3
R2 R3 R4
2.41 2.47 4.00
0.32 0.19 0.69
0.93 0.76 0.58
0.25 0.58 1.00
1.44 0.49 0.80
0.23 0.16 0.72
0.33 0.57 0.99
0.04 0.24 1.20
0.03 0.46 0.26
0.14 0.40 0.95
0.05 0.35 1.30
0.3744 0.7049 1.8075
0.8091 1.0068 3.2546
Fig. 2 Half-normal probability plots (A) and Pareto charts (B) for R1, R2, R3 and R4.
Table 3 Evaluation of factors effects.
Response (a) (b) (c) (d)
R1 CþG G CþG CþG
R2 AþCþE AþCþE AþCþE AþCþE
R3 AþC A A A
R4 A A A A
(a)Signiﬁcant effects at a¼0.05 from comparation with critical effects from negligible effects
(b)Signiﬁcant effects at a¼0.05 from algorithm of Dong
(c)Signiﬁcant effects from the half–normal probability plot
(d)Signiﬁcant effects from Pareto chart
Experimental design in pharmaceutical analysis of raloxifene 49One of the main advantages of the introduction of experi-
mental design in robustness testing is the possibility to deﬁne
SST using the worst case situations as it is recommended byVander Heyden et al. [4]. These worst-case conditions could
be predicted from the calculated effects. The worst-case
situation is then the factors combination giving the worst
Table 4 Nonsigniﬁcant intervals for signiﬁcant variables (dummy variable and Dong’s methods).
Response Signiﬁcant
factor
Nonsigniﬁcant interval obtained from Ecritical from
dummies at a¼0.05
Nonsigniﬁcant interval obtained from Ecritical from
Dong’s algorithm at a¼0.05
R1 C 5.64–6.36 -
G 4.40–4.60 4.31–4.69
R2 A 43.84–44.16 43.66–44.34
C 5.80–6.20 5.56–6.43
E 43.70–46.30 42.19–47.81
R3 A 43.71–44.29 43.59–44.41
C 5.54–6.46 -
R4 A 43.55–44.45 43.19–44.81
A, acetonitrile content (%); C, sodium dodecyl sulfate (SDS) content in water phase (mM); E, column temperature (1C); G, pH of the
mobile phase
Table 5 Important data for method validation.
Parameter Raloxifene hydrochloride Imp. 1 Imp. 2 Imp. 3 Imp. 4
Linearity range (mg/mL) 10–120 0.05–0.60
Slope (a) 43486.57 76.57 75.02 68.70 71.86
Intercept (b) 13.33 0.81 1.05 0.49 0.83
Correlation coefﬁcient (r) 0.9999 0.9997 0.9972 0.9992 0.9959
Accuracy given as recovery (%)
Low leveln 94.9470.47 87.4977.73 92.1976.54 102.9470.06 102.9470.06
Medium leveln 95.2970.38 80.0872.53 88.7472.99 92.0971.17 82.6874.67
High leveln 97.1470.22 81.0571.16 86.7872.92 93.1471.73 91.1573.35
Precision RSD (%) 1.5 2.7 2.8 2.9 5.2
RSD, Relative Standard Deviation.
nLow level corresponds to 80%; medium level corresponds to 100%, and high level corresponds to 120%.
Fig. 3 Chromatograms of placebo (A), laboratory mixture (B) (0.937 min, Imp. 2; 1.193 min, Imp. 1; 3.132 min, raloxifene
hydrochloride; 3.802 min, Imp. 3; and 10.057 min, Imp. 4) and analyzed sample (C) obtained under the optimal chromatographic
conditions: SunFire C18 (3 mm 100 mm, 3.5 mm particle size), acetonitrile–water phase (6 mM SDS, pH 4.5 adjusted with ortho-
phosphoric acid) 44:56 (v/v), ﬂow rate of 1 mL/min, temperature of 45 1C, and wavelength of 254 nm.
B. Jancˇic´ Stojanovic´ et al.50result for response. To deﬁne the worst-case conditions only
the statistically signiﬁcant factors (at a¼0.05) and the ones
that come close to it (signiﬁcant at a¼0.1) are considered [4].
Using Eq. (2) the worst result can be derived.
Y ¼ b0 þ
EF1
2
nF1 þ
EF2
2
nF2 þ . . .þ
EFk
2
nFk ð2Þ
where Y represents the response, b0 is the average design
result, EFi is the effect of the factor considered for the worst-
case experiment and Fi is the level of this factor (–1 or þ1).Non-important factors are kept at nominal value (Fk¼0).
Calculated values for SST are 1.625, 10.84, 4.075 and 16.34 for
R1, R2, R3 and R4, respectively. It is obvious that only value
for R1 could be considered as critical and its values should be
tested always.
After all in this investigations, the other parameters included
in the method validation are tested and results are given in
Table 5. This includes linearity, accuracy and precision testing, as
well as the determination of limit of detection (LOD) and limit of
quantiﬁcation (LOQ) for the impurities.
Experimental design in pharmaceutical analysis of raloxifene 51Linear relationships of the peak areas vs. concentration for
the concentration ranges mentioned above were obtained for
raloxifene hydrochloride and all impurities. As the correlation
coefﬁcient (r) for the calibration curves of raloxifene hydro-
chloride and its impurities were greater than 0.9959 it can be
concluded that the calibration curves were within the linearity
acceptance criteria.
To evaluate the method accuracy, the recovery values for
laboratory mixtures were calculated. Namely, certain amount
of active substance and impurities were added to placebo and
all procedure for tablets was followed in order to conﬁrm that
there are no interactions. Obtained values for all conducted
tests are within the required values [25]. RSD values for
precision were lower than 5% for impurities and 1.5% for
raloxifene hydrochloride.
For the quantitative analysis of impurities it was important
to deﬁne the values of LOD and LOQ. The signal-to-noise
ratio of 3.3:1 and 10:1 were taken as LOD and LOQ,
respectively, and further conﬁrmed by taking dilutions from
the secondary stock solution till the peak area obtained was
3.3 times (for LOD) and 10 times (for LOQ) bigger than the
standard deviation of blank solution after six injections. The
obtained values for all impurities were 0.025 mg/mL and
0.008 mg/mL for LOQ and LOD, respectively.
Chromatograms of placebo (A), laboratory mixture (B) and
the analyzed sample (C) are presented in Fig. 3. Finally, tablets
containing raloxifene hydrochloride were analyzed and content
of raloxifene hydrochloride was 57.6 mg/tbl (96%) and Imp. 1
was 0.08%. Other impurities’ contents (Imp. 2, Imp. 3 and
Imp. 4), under validated chromatographic conditions, were below
LOQ. So, it could be concluded that contents of all impurities are
below maximal allowed level of 0.5%.4. Conclusion
In this paper, validation of a new LC method proposed for the
quantiﬁcation of raloxifene hydrochloride and its four impu-
rities was presented. The suitability of the method was
conﬁrmed by testing the appropriate performance parameters.
In that way the realistic representation of the quality and
reliability of the proposed method is acquired. Firstly, the
robustness of the newly developed method was tested by the
application of Plackett–Burman design. Statistical and gra-
phical methods are used to designate the factors that inﬂuence
method’s robustness signiﬁcantly. In order to enable the
proper control of the proposed method during the routine
application, non-signiﬁcant intervals for signiﬁcant factors
and parameters for system suitability testing were deﬁned.
Also, all the other validation parameters were statistically
evaluated and method’s adequacy for the analysis of pharma-
ceuticals containing raloxifene was conﬁrmed.Acknowledgments
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